The current trial phase and status can be verified via ClinicalTrials.gov or the EU Clinical Trials Register
Barragn-Zarate, G
Li Q, Li Q-Q, Jia J-N, Sun Q-Y, Zhou H-H, Jin W-L, Mao X-Y (2019) Baicalein exerts neuroprotective effects in FeCl3-induced posttraumatic epileptic seizures via suppressing ferroptosis
Kim KS, Egan JM, Jang HJ
Therefore, the dosing conditions used in the phase III clinical trial program were for oral semaglutide to be administered once daily on waking, in a fasting state, with up to 120 mL of water, and then waiting for 30 min before consumption of any food, drink, or other oral medications
The medication is delivered via subcutaneous injection (just under the skin) using a prefilled pen or syringe, taking only a few seconds to administer